Nubeqa (generic name: darolutamide) is an androgen receptor inhibitor used in the treatment of adult men with either non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). In cases of mHSPC, Nubeqa may be used in combination with docetaxel, which is a chemotherapy medication used to treat several types of cancer.
Darolutamide works by blocking the action of androgens, including testosterone, which are male sex hormones that can promote the growth of prostate cancer cells. Inhibiting the androgen receptor slows down or halts the proliferation of cancer cells.
Nubeqa is designed to be well-tolerated, even when used alongside other prostate cancer treatments. It has been shown to delay disease progression and prolong survival.
Caution
Nubeqa can cause birth defects. Men should use effective contraception when engaging in sex with a fertile woman when starting treatment with Nubeqa and for at least one week after treatment stops.
Dosage
Take the medicine exactly as outlined on the label and in accord with the prescribing doctor’s instructions. The tablets should be taken at the same time each day, and the dosing schedule should be maintained consistently. Treatment with Nubeqa should not be discontinued without medical advice.
The usual dose of Nubeqa is two 300 mg tablets twice daily. The tablets should be taken with food and swallowed whole with a full glass of water. Do not split, chew or crush them. In cases where the patient has liver or kidney impairment, a doctor may reduce the dose to one 300 mg tablet twice daily.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.
Read the information leaflet that comes with the medication.
Most people who use Nubeqa do not experience any adverse side effects. Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include rashes, fatigue, anemia, and some disturbances of blood chemistry and liver function. Doctors usually monitor for these changes with regular blood tests.
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Nubeqa is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).
nmCRPC refers to prostate cancer that no longer responds to testosterone-lowering therapies and has not yet spread to other parts of the body. Common symptoms include frequent or painful urination, blood in urine or semen, erectile dysfunction, and pelvic discomfort. Despite being non-metastatic, the cancer is aggressive and continues to progress without visible metastases.
mHSPC is a stage of prostate cancer that has spread (metastasized) but still responds to hormone therapy. Symptoms may include bone pain, unexplained weight loss, fatigue, and urinary obstruction. In mHSPC, Nubeqa is often used in combination with chemotherapy agents like docetaxel to enhance outcomes.